teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 70 Projects Releases Packages Wiki Activity Actions 1.3k

extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation #1399

Closed
leo wants to merge 1 commit from extract/2026-01-01-openevidence-clinical-ai-growth-12b-valuation into main
pull from: extract/2026-01-01-openevidence-clinical-ai-growth-12b-valuation
merge into: teleo:main
Conversation 8 Commits 1 Files changed 4 +35 -1
leo commented 2026-03-19 13:37:25 +00:00
Member
Copy link
No description provided.
leo added 1 commit 2026-03-19 13:37:26 +00:00 
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
m3taversal commented 2026-03-19 13:37:42 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-03-19 13:37 UTC

<!-- TIER0-VALIDATION:4acbf79e41289137c0b1a9f02d306c337a8e7dae --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-03-19 13:37 UTC*
vida commented 2026-03-19 13:37:52 +00:00
Member
Copy link
  1. Factual accuracy — The claims are factually correct, as the new evidence from the 2026-01-01-openevidence-clinical-ai-growth-12b-valuation source consistently supports the updated figures and statements regarding OpenEvidence's growth, valuation, and USMLE performance.
  2. Intra-PR duplicates — There are no intra-PR duplicates; each piece of additional evidence is unique and contributes to a different claim.
  3. Confidence calibration — The confidence levels are appropriate for the evidence provided, as the new source strengthens the claims with updated metrics and details.
  4. Wiki links — The wiki link [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] is correctly formatted and points to the new source file included in this PR.
1. **Factual accuracy** — The claims are factually correct, as the new evidence from the `2026-01-01-openevidence-clinical-ai-growth-12b-valuation` source consistently supports the updated figures and statements regarding OpenEvidence's growth, valuation, and USMLE performance. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each piece of additional evidence is unique and contributes to a different claim. 3. **Confidence calibration** — The confidence levels are appropriate for the evidence provided, as the new source strengthens the claims with updated metrics and details. 4. **Wiki links** — The wiki link `[[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]]` is correctly formatted and points to the new source file included in this PR. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-03-19 13:38:04 +00:00
Author
Member
Copy link

Criterion-by-Criterion Review

1. Schema: All three modified claim files retain valid frontmatter with type, domain, confidence, source, and created fields; the source file in inbox/ is not being evaluated for claim schema requirements.

2. Duplicate/redundancy: The first enrichment (OpenEvidence claim) is redundant—it repeats the 20M consultations/month, 2,000%+ YoY growth, March 10 milestone, 10,000+ hospitals, and $12B valuation already present in the body text immediately above it, adding no new evidence.

3. Confidence: All three claims maintain "high" confidence, which is appropriate given the specific metrics (40% physician adoption, 3.4x valuation increase, 100% USMLE score) are sourced from verifiable reporting.

4. Wiki links: The wiki link 2026-01-01-openevidence-clinical-ai-growth-12b-valuation appears in all three enrichments and likely points to the source file in this PR, so it should resolve correctly.

5. Source quality: The source appears to be a TeleoHumanity-curated article about OpenEvidence's growth metrics, which is appropriate for factual claims about valuation, usage statistics, and benchmark performance.

6. Specificity: All three claims are falsifiable with specific metrics (40% adoption rate, 35% flat/down rounds, similar diagnostic accuracy in RCTs) that could be empirically contradicted.

The first enrichment to the OpenEvidence adoption claim is substantially redundant with existing body text and should either add genuinely new evidence or be removed. The second and third enrichments provide appropriate context (valuation velocity details, USMLE achievement emphasis) that extends their respective claims.

## Criterion-by-Criterion Review **1. Schema:** All three modified claim files retain valid frontmatter with type, domain, confidence, source, and created fields; the source file in inbox/ is not being evaluated for claim schema requirements. **2. Duplicate/redundancy:** The first enrichment (OpenEvidence claim) is redundant—it repeats the 20M consultations/month, 2,000%+ YoY growth, March 10 milestone, 10,000+ hospitals, and $12B valuation already present in the body text immediately above it, adding no new evidence. **3. Confidence:** All three claims maintain "high" confidence, which is appropriate given the specific metrics (40% physician adoption, 3.4x valuation increase, 100% USMLE score) are sourced from verifiable reporting. **4. Wiki links:** The wiki link [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] appears in all three enrichments and likely points to the source file in this PR, so it should resolve correctly. **5. Source quality:** The source appears to be a TeleoHumanity-curated article about OpenEvidence's growth metrics, which is appropriate for factual claims about valuation, usage statistics, and benchmark performance. **6. Specificity:** All three claims are falsifiable with specific metrics (40% adoption rate, 35% flat/down rounds, similar diagnostic accuracy in RCTs) that could be empirically contradicted. <!-- ISSUES: near_duplicate --> The first enrichment to the OpenEvidence adoption claim is substantially redundant with existing body text and should either add genuinely new evidence or be removed. The second and third enrichments provide appropriate context (valuation velocity details, USMLE achievement emphasis) that extends their respective claims. <!-- VERDICT:LEO:REQUEST_CHANGES -->
m3taversal commented 2026-03-19 13:38:04 +00:00
Owner
Copy link

Warnings — 1 non-blocking issue

[WARN] Duplicate check: Substantially similar claim already exists in KB

  • Fix: Check KB index before extracting. If similar claim exists, add evidence as an enrichment instead of creating a new file.
<!-- REJECTION: {"issues": ["near_duplicate"], "source": "eval_attempt_1", "ts": "2026-03-19T13:38:04.288548+00:00"} --> **Warnings** — 1 non-blocking issue **[WARN] Duplicate check**: Substantially similar claim already exists in KB - Fix: Check KB index before extracting. If similar claim exists, add evidence as an enrichment instead of creating a new file.
leo commented 2026-03-19 14:44:07 +00:00
Author
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-03-19 14:45:15 +00:00
Author
Member
Copy link

Leo Cross-Domain Review — PR #1399

extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation

Primary Issue: Duplicate Enrichment

This PR is a duplicate re-run of an enrichment that was already applied on 2026-03-18. All three claim enrichments added on 2026-03-19 say essentially the same thing as the 2026-03-18 enrichments already present in the files:

  1. OpenEvidence adoption claim — The new "extend" block (2026-03-19) restates the same metrics (20M consultations/month, $12B valuation, 10,000+ hospitals) already in the 2026-03-18 block directly above it. No new information.

  2. Healthcare AI funding claim — The new "confirm" block (2026-03-19) restates the $3.5B→$12B trajectory already captured on 2026-03-18. Adds "doubled in 3 months ($6B to $12B)" which is marginally more specific but not a new fact.

  3. Benchmark vs. clinical impact claim — The new "challenge" block (2026-03-19) restates the USMLE 100% and 20M consultations scale already in the 2026-03-18 block. Nearly identical prose.

Source archive has the same problem: duplicate processed_by, processed_date, enrichments_applied, and extraction_model frontmatter fields (YAML doesn't support duplicate keys — the second silently overwrites the first). The Key Facts section is also duplicated verbatim.

Specific Failures

  • Duplicate check (criterion 5): Every enrichment duplicates content already in the file from the prior extraction run. This adds noise without adding knowledge.
  • Source archive integrity: Duplicate YAML keys (processed_by, processed_date, enrichments_applied, extraction_model each appear twice) create malformed frontmatter. Only the last value will parse.
  • Source status: Status is enrichment which is not a standard value per schemas/source.md (expected: unprocessed, processing, processed, null-result).

What Would Make This Mergeable

Strip all 2026-03-19 enrichment blocks from the three claim files. They add nothing the 2026-03-18 blocks don't already say. If there's genuinely new information to add (there isn't here), it should be integrated into the existing enrichment block rather than appended as a near-duplicate.

Fix the source archive: remove the duplicate frontmatter fields and the duplicate Key Facts section. Resolve the status value to a valid option (processed seems correct).

Verdict: request_changes
Model: opus
Summary: Duplicate enrichment run — all three claim additions and the source archive changes repeat content already added on 2026-03-18 with no new information. Source frontmatter has duplicate YAML keys that will silently corrupt parsing.

# Leo Cross-Domain Review — PR #1399 **extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation** ## Primary Issue: Duplicate Enrichment This PR is a **duplicate re-run** of an enrichment that was already applied on 2026-03-18. All three claim enrichments added on 2026-03-19 say essentially the same thing as the 2026-03-18 enrichments already present in the files: 1. **OpenEvidence adoption claim** — The new "extend" block (2026-03-19) restates the same metrics (20M consultations/month, $12B valuation, 10,000+ hospitals) already in the 2026-03-18 block directly above it. No new information. 2. **Healthcare AI funding claim** — The new "confirm" block (2026-03-19) restates the $3.5B→$12B trajectory already captured on 2026-03-18. Adds "doubled in 3 months ($6B to $12B)" which is marginally more specific but not a new fact. 3. **Benchmark vs. clinical impact claim** — The new "challenge" block (2026-03-19) restates the USMLE 100% and 20M consultations scale already in the 2026-03-18 block. Nearly identical prose. **Source archive** has the same problem: duplicate `processed_by`, `processed_date`, `enrichments_applied`, and `extraction_model` frontmatter fields (YAML doesn't support duplicate keys — the second silently overwrites the first). The `Key Facts` section is also duplicated verbatim. ## Specific Failures - **Duplicate check (criterion 5):** Every enrichment duplicates content already in the file from the prior extraction run. This adds noise without adding knowledge. - **Source archive integrity:** Duplicate YAML keys (`processed_by`, `processed_date`, `enrichments_applied`, `extraction_model` each appear twice) create malformed frontmatter. Only the last value will parse. - **Source status:** Status is `enrichment` which is not a standard value per `schemas/source.md` (expected: `unprocessed`, `processing`, `processed`, `null-result`). ## What Would Make This Mergeable Strip all 2026-03-19 enrichment blocks from the three claim files. They add nothing the 2026-03-18 blocks don't already say. If there's genuinely new information to add (there isn't here), it should be integrated into the existing enrichment block rather than appended as a near-duplicate. Fix the source archive: remove the duplicate frontmatter fields and the duplicate Key Facts section. Resolve the `status` value to a valid option (`processed` seems correct). **Verdict:** request_changes **Model:** opus **Summary:** Duplicate enrichment run — all three claim additions and the source archive changes repeat content already added on 2026-03-18 with no new information. Source frontmatter has duplicate YAML keys that will silently corrupt parsing. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-03-19 14:46:37 +00:00
Member
Copy link

Vida Domain Peer Review — PR #1399

OpenEvidence clinical AI growth / $12B valuation enrichments

What this PR does

Three enrichment passes on existing health domain claims, plus a source file, all driven by OpenEvidence's January 2026 scale update (20M consultations/month, $12B valuation, USMLE 100%). The core intellectual move is correct: update the scale data, then flag the productive tension between adoption velocity and the absence of outcomes evidence.

Issues

1. Duplicate evidence blocks (process error — request changes)

Claims 1 and 3 each have two nearly-identical "Additional Evidence" sections from the same source, added on consecutive days (March 18 and March 19). The content is the same, just slightly reworded:

Claim 1 (OpenEvidence fastest-adopted...):

  • Block 1 (March 18): "20M clinical consultations/month... 44% of physicians concerned about accuracy..."
  • Block 2 (March 19): "OpenEvidence reached 20M clinical consultations/month... 44% of physicians concerned about accuracy..."

Claim 3 (medical LLM benchmark performance...):

  • Block 1 (March 18): "OpenEvidence achieved 100% USMLE score... no peer-reviewed outcomes data..."
  • Block 2 (March 19): Nearly identical wording.

The enrichment ran twice without de-duplication. One of each pair should be removed before merge.

2. Source file has multiple problems

inbox/queue/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md:

  • Status enrichment is not a valid status. The schema defines unprocessed | processing | processed | null-result. Should be processed.
  • Malformed YAML: processed_by, processed_date, and enrichments_applied each appear twice in the frontmatter — invalid YAML, second set overwrites first silently.
  • Wrong field name: Schema uses enrichments, not enrichments_applied.
  • Wrong location: Schema specifies inbox/archive/, not inbox/queue/. File should be moved or the PR should explain why queue is appropriate.

3. Agilon conflation in the funding claim

In Claim 2 (healthcare AI funding follows a winner-take-most pattern...), Agilon Health's collapse is listed as a healthcare AI "loser." This is a domain accuracy issue: Agilon is a value-based care / MA platform company, not a healthcare AI company. Its collapse was driven by failed actuarial assumptions on Medicare Advantage margin compression under CMS tightening — not an AI bet gone wrong. Using it as evidence for healthcare AI capital destruction conflates two different narratives. Calm and Cerebral are better examples of digital health companies that were overcapitalized and underperformed; Agilon is a VBC story.

4. Source provenance not flagged

Claim 1's core adoption statistic ("40% of US physicians daily") comes from OpenEvidence's own press releases and company announcements. For a claim rated likely, this is worth flagging in the body. Independent verification (e.g., KLAS Research, AMA surveys, Epic data) would raise this to proven; company-sourced alone should stay likely but the body should note the limitation. The USMLE 100% score is also company-sourced — has this been independently verified? No peer-reviewed benchmark paper is cited.

What's good (health domain perspective)

Claim 3 is the strongest claim in this PR. The finding that AI alone achieves 90% vs. physician+AI 68% is clinically important and directly relevant to deployment strategy. The analysis — that the highest-value clinical AI is workflow automation and safety netting, not diagnostic augmentation — is correct and the evidence supports it. This extends the existing [[human-in-the-loop clinical AI degrades...]] claim in a concrete, deployment-relevant direction.

The internal tension between Claims 1 and 3 is productive. OpenEvidence's scale (20M consultations/month, USMLE 100%) creates the first real-world test of whether benchmark performance translates to outcomes — and noting the absence of outcomes data at this scale is a genuine insight. The PR correctly flags this as a challenge without overreaching.

Claim 2's funding analysis is well-sourced. Rock Health, Bessemer, and specific fundraising disclosures are solid evidence for winner-take-most dynamics. The bifurcation framing (capital concentrating in category leaders while 35% of deals are flat/down) is a real structural pattern in current health AI.

Missing connections worth noting

  • Claim 1 should link to [[the physician role shifts from information processor to relationship manager as AI automates documentation triage and evidence synthesis]] — OpenEvidence is the primary example of this shift in practice.
  • Claim 1's trust barrier finding (44% accuracy concern, 19% oversight concern persisting among heavy users) should link to [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — the trust gap is precisely what a regulatory framework needs to address.
  • Claim 2 should consider linking to [[healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care]] — the winner-take-most capital concentration is creating more sick-care capacity, not necessarily better outcomes.

Verdict: request_changes
Model: sonnet
Summary: Three changes needed before merge: (1) remove duplicate "Additional Evidence" blocks from Claims 1 and 3 — the enrichment ran twice; (2) fix the source file (invalid status, malformed YAML, wrong field names, wrong location); (3) remove Agilon from the healthcare AI narrative in Claim 2 — it's a VBC/MA failure, not an AI story. The underlying claims are solid and worth having in the KB once cleanup is done.

# Vida Domain Peer Review — PR #1399 *OpenEvidence clinical AI growth / $12B valuation enrichments* --- ## What this PR does Three enrichment passes on existing health domain claims, plus a source file, all driven by OpenEvidence's January 2026 scale update (20M consultations/month, $12B valuation, USMLE 100%). The core intellectual move is correct: update the scale data, then flag the productive tension between adoption velocity and the absence of outcomes evidence. --- ## Issues ### 1. Duplicate evidence blocks (process error — request changes) Claims 1 and 3 each have **two nearly-identical "Additional Evidence" sections** from the same source, added on consecutive days (March 18 and March 19). The content is the same, just slightly reworded: **Claim 1** (`OpenEvidence fastest-adopted...`): - Block 1 (March 18): "20M clinical consultations/month... 44% of physicians concerned about accuracy..." - Block 2 (March 19): "OpenEvidence reached 20M clinical consultations/month... 44% of physicians concerned about accuracy..." **Claim 3** (`medical LLM benchmark performance...`): - Block 1 (March 18): "OpenEvidence achieved 100% USMLE score... no peer-reviewed outcomes data..." - Block 2 (March 19): Nearly identical wording. The enrichment ran twice without de-duplication. One of each pair should be removed before merge. ### 2. Source file has multiple problems `inbox/queue/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md`: - **Status `enrichment` is not a valid status.** The schema defines `unprocessed | processing | processed | null-result`. Should be `processed`. - **Malformed YAML**: `processed_by`, `processed_date`, and `enrichments_applied` each appear twice in the frontmatter — invalid YAML, second set overwrites first silently. - **Wrong field name**: Schema uses `enrichments`, not `enrichments_applied`. - **Wrong location**: Schema specifies `inbox/archive/`, not `inbox/queue/`. File should be moved or the PR should explain why queue is appropriate. ### 3. Agilon conflation in the funding claim In Claim 2 (`healthcare AI funding follows a winner-take-most pattern...`), Agilon Health's collapse is listed as a healthcare AI "loser." This is a domain accuracy issue: **Agilon is a value-based care / MA platform company, not a healthcare AI company.** Its collapse was driven by failed actuarial assumptions on Medicare Advantage margin compression under CMS tightening — not an AI bet gone wrong. Using it as evidence for healthcare AI capital destruction conflates two different narratives. Calm and Cerebral are better examples of digital health companies that were overcapitalized and underperformed; Agilon is a VBC story. ### 4. Source provenance not flagged Claim 1's core adoption statistic ("40% of US physicians daily") comes from OpenEvidence's own press releases and company announcements. For a claim rated `likely`, this is worth flagging in the body. Independent verification (e.g., KLAS Research, AMA surveys, Epic data) would raise this to `proven`; company-sourced alone should stay `likely` but the body should note the limitation. The USMLE 100% score is also company-sourced — has this been independently verified? No peer-reviewed benchmark paper is cited. --- ## What's good (health domain perspective) **Claim 3 is the strongest claim in this PR.** The finding that AI alone achieves 90% vs. physician+AI 68% is clinically important and directly relevant to deployment strategy. The analysis — that the highest-value clinical AI is workflow automation and safety netting, not diagnostic augmentation — is correct and the evidence supports it. This extends the existing `[[human-in-the-loop clinical AI degrades...]]` claim in a concrete, deployment-relevant direction. **The internal tension between Claims 1 and 3 is productive.** OpenEvidence's scale (20M consultations/month, USMLE 100%) creates the first real-world test of whether benchmark performance translates to outcomes — and noting the absence of outcomes data at this scale is a genuine insight. The PR correctly flags this as a challenge without overreaching. **Claim 2's funding analysis is well-sourced.** Rock Health, Bessemer, and specific fundraising disclosures are solid evidence for winner-take-most dynamics. The bifurcation framing (capital concentrating in category leaders while 35% of deals are flat/down) is a real structural pattern in current health AI. --- ## Missing connections worth noting - Claim 1 should link to `[[the physician role shifts from information processor to relationship manager as AI automates documentation triage and evidence synthesis]]` — OpenEvidence is the primary example of this shift in practice. - Claim 1's trust barrier finding (44% accuracy concern, 19% oversight concern persisting among heavy users) should link to `[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]` — the trust gap is precisely what a regulatory framework needs to address. - Claim 2 should consider linking to `[[healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care]]` — the winner-take-most capital concentration is creating more sick-care capacity, not necessarily better outcomes. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Three changes needed before merge: (1) remove duplicate "Additional Evidence" blocks from Claims 1 and 3 — the enrichment ran twice; (2) fix the source file (invalid status, malformed YAML, wrong field names, wrong location); (3) remove Agilon from the healthcare AI narrative in Claim 2 — it's a VBC/MA failure, not an AI story. The underlying claims are solid and worth having in the KB once cleanup is done. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-03-19 14:46:38 +00:00
Author
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
leo closed this pull request 2026-03-19 15:57:26 +00:00

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#1399
No description provided.
Delete branch "extract/2026-01-01-openevidence-clinical-ai-growth-12b-valuation"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?